Literature DB >> 33291793

The U94 Gene of Human Herpesvirus 6: A Narrative Review of Its Role and Potential Functions.

Elisabetta Caselli1, Maria D'Accolti1, Francesca Caccuri2, Irene Soffritti1, Valentina Gentili1, Daria Bortolotti1, Antonella Rotola1, Enzo Cassai1, Simona Fiorentini2, Alberto Zani2, Arnaldo Caruso2, Roberta Rizzo1, Dario Di Luca3.   

Abstract

Human herpesvirus 6 (HHV-6) is a β-herpesvirus that is highly prevalent in the human population. HHV-6 comprises two recognized species (HHV-6A and HHV-6B). Despite different cell tropism and disease association, HHV-6A/B show high genome homology and harbor the conserved U94 gene, which is limited to HHV-6 and absent in all the other human herpesviruses. U94 has key functions in the virus life cycle and associated diseases, having demonstrated or putative roles in virus replication, integration, and reactivation. During natural infection, U94 elicits an immune response, and the prevalence and extent of the anti-U94 response are associated with specific diseases. Notably, U94 can entirely reproduce some virus effects at the cell level, including inhibition of cell migration, induction of cytokines and HLA-G expression, and angiogenesis inhibition, supporting a direct U94 role in the development of HHV-6-associated diseases. Moreover, specific U94 properties, such as the ability to modulate angiogenesis pathways, have been exploited to counteract cancer development. Here, we review the information available on this key HHV-6 gene, highlighting its potential uses.

Entities:  

Keywords:  U94 exploitation; U94 functions; human herpesvirus 6

Mesh:

Substances:

Year:  2020        PMID: 33291793      PMCID: PMC7762089          DOI: 10.3390/cells9122608

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  128 in total

1.  Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Authors:  Ioannis Politikos; Malgorzata McMasters; Christine Bryke; David Avigan; Vassiliki A Boussiotis
Journal:  Blood Adv       Date:  2018-06-26

2.  Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients.

Authors:  D V Ablashi; H B Eastman; C B Owen; M M Roman; J Friedman; J B Zabriskie; D L Peterson; G R Pearson; J E Whitman
Journal:  J Clin Virol       Date:  2000-05       Impact factor: 3.168

Review 3.  Clinical impact of primary infection with roseoloviruses.

Authors:  Brenda L Tesini; Leon G Epstein; Mary T Caserta
Journal:  Curr Opin Virol       Date:  2014-10-14       Impact factor: 7.090

4.  Analysis of human herpesvirus-6 IE1 sequence variation in clinical samples.

Authors:  Richard Stanton; Gavin W G Wilkinson; Julie D Fox
Journal:  J Med Virol       Date:  2003-12       Impact factor: 2.327

5.  Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.

Authors:  John R Crawford; Maria Rita Santi; Robbie Cornelison; Satu-Leena Sallinen; Hannu Haapasalo; Tobey J MacDonald
Journal:  J Neurooncol       Date:  2009-05-08       Impact factor: 4.130

6.  Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).

Authors:  P H Levine; N Jahan; P Murari; M Manak; E S Jaffe
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

7.  Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals.

Authors:  R W Cone; M L Huang; R Ashley; L Corey
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

8.  Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases.

Authors:  Francesco Broccolo; Francesco Drago; Giulia Cassina; Andrea Fava; Lisa Fusetti; Barbara Matteoli; Luca Ceccherini-Nelli; Maria Grazia Sabbadini; Paolo Lusso; Aurora Parodi; Mauro S Malnati
Journal:  J Med Virol       Date:  2013-11       Impact factor: 2.327

9.  Identification of human herpesvirus-6 as a causal agent for exanthem subitum.

Authors:  K Yamanishi; T Okuno; K Shiraki; M Takahashi; T Kondo; Y Asano; T Kurata
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

10.  The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease.

Authors:  Recep Dursun; Selami Aykut Temiz
Journal:  Dermatol Ther       Date:  2020-06-29       Impact factor: 3.858

View more
  2 in total

Review 1.  Viral Proteins with PxxP and PY Motifs May Play a Role in Multiple Sclerosis.

Authors:  Keng-Shuo Pi; Yurou Sang; Suzana K Straus
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

Review 2.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.